Trial · NCT04781647
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With an Adverse Event | Up to 60 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With Premature Discontinuation of Treatment | Up to 60 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With a Laboratory Abnormality | Up to 60 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Mean Change From Baseline in HBV pgRNA | Baseline and at pre-specified time points up to 60 weeks | Due to early termination of the study, not all subjects reached Week 48. | log10 U/mL | MEAN |
| SECONDARY | Mean Change From Baseline HBV DNA | Baseline and at pre-specified time points up to 60 weeks | Due to early termination of the study, not all subjects reached Week 48. | log10 IU/mL | MEAN |
| SECONDARY | Mean Change From Baseline in HBeAg | Baseline and at pre-specified time points up to 60 weeks | Due to early termination of the study, not all subjects reached Week 48. | log10 IU/mL | MEAN |
| SECONDARY | Mean Change From Baseline in HBcrAg | Baseline and at pre-specified time points up to 60 weeks | Due to early termination of the study, not all subjects reached Week 48. | log10 kU/mL | MEAN |
| SECONDARY | Mean Change From Baseline in HBsAg | Baseline and at pre-specified time points up to 60 weeks | Due to early termination of the study, not all subjects reached Week 48. | log10 IU/mL | MEAN |
| SECONDARY | Number of Participants With Normalized Alanine Aminotransferase (ALT) | Baseline and at pre-specified time points up to 60 weeks | Due to early termination of the study, data were not collected or analyzed for secondary outcomes. | ||
| SECONDARY | Plasma Concentration of ABI-H0731 | Predose on Day 1, Week 4, and Week 24 and at pre-specified time points postdose up to Week 24 | No ABI-H0731 PK data were collected from the ETV + Peg-IFNα group until Week 24 when they started receiving ABI-H0731. | ng/mL | MEAN |
| SECONDARY | Incidence of HBV Variants With Reduced Susceptibility to ABI-H0731 | Pre-specified time points up to 60 weeks | No cases met the criteria for resistance analysis. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04781647/outcomes